vs
Side-by-side financial comparison of Boston Scientific (BSX) and Cincinnati Financial (CINF). Click either name above to swap in a different company.
Boston Scientific is the larger business by last-quarter revenue ($5.2B vs $2.8B, roughly 1.8× Cincinnati Financial). Boston Scientific runs the higher net margin — 25.7% vs 9.6%, a 16.2% gap on every dollar of revenue. On growth, Boston Scientific posted the faster year-over-year revenue change (11.6% vs -1.7%). Over the past eight quarters, Boston Scientific's revenue compounded faster (12.4% CAGR vs 5.2%).
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Cincinnati Financial Corporation offers property and casualty insurance, its main business, through The Cincinnati Insurance Company, The Cincinnati Indemnity Company and The Cincinnati Casualty Company. The company has 1.01% of the domestic property and casualty insurance premiums, which ranks it as the 20th largest insurance company by market share in the U.S.
BSX vs CINF — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $5.2B | $2.8B |
| Net Profit | $1.3B | $274.0M |
| Gross Margin | 69.5% | — |
| Operating Margin | — | — |
| Net Margin | 25.7% | 9.6% |
| Revenue YoY | 11.6% | -1.7% |
| Net Profit YoY | 99.0% | 404.4% |
| EPS (diluted) | $0.90 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $5.2B | $2.8B | ||
| Q4 25 | $5.3B | $3.1B | ||
| Q3 25 | $5.1B | $3.7B | ||
| Q2 25 | $5.1B | $3.2B | ||
| Q1 25 | $4.7B | $2.6B | ||
| Q4 24 | $4.6B | $2.5B | ||
| Q3 24 | $4.2B | $3.3B | ||
| Q2 24 | $4.1B | $2.5B |
| Q1 26 | $1.3B | $274.0M | ||
| Q4 25 | $670.0M | $676.0M | ||
| Q3 25 | $755.0M | $1.1B | ||
| Q2 25 | $795.0M | $685.0M | ||
| Q1 25 | $672.0M | $-90.0M | ||
| Q4 24 | $563.0M | $405.0M | ||
| Q3 24 | $468.0M | $820.0M | ||
| Q2 24 | $322.0M | $312.0M |
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | 67.7% | — | ||
| Q1 25 | 68.8% | — | ||
| Q4 24 | 67.8% | — | ||
| Q3 24 | 68.8% | — | ||
| Q2 24 | 69.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 27.2% | ||
| Q3 25 | 20.7% | 37.9% | ||
| Q2 25 | 16.2% | 26.3% | ||
| Q1 25 | 19.8% | -5.0% | ||
| Q4 24 | 14.8% | 18.9% | ||
| Q3 24 | 17.4% | 31.3% | ||
| Q2 24 | 12.6% | 15.2% |
| Q1 26 | 25.7% | 9.6% | ||
| Q4 25 | 12.7% | 21.9% | ||
| Q3 25 | 14.9% | 30.1% | ||
| Q2 25 | 15.7% | 21.1% | ||
| Q1 25 | 14.4% | -3.5% | ||
| Q4 24 | 12.3% | 16.0% | ||
| Q3 24 | 11.1% | 24.7% | ||
| Q2 24 | 7.8% | 12.3% |
| Q1 26 | $0.90 | — | ||
| Q4 25 | $0.45 | $4.29 | ||
| Q3 25 | $0.51 | $7.11 | ||
| Q2 25 | $0.53 | $4.34 | ||
| Q1 25 | $0.45 | $-0.57 | ||
| Q4 24 | $0.38 | $2.57 | ||
| Q3 24 | $0.32 | $5.20 | ||
| Q2 24 | $0.22 | $1.98 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.2B |
| Total DebtLower is stronger | — | $816.0M |
| Stockholders' EquityBook value | — | $15.7B |
| Total Assets | — | $41.2B |
| Debt / EquityLower = less leverage | — | 0.05× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.0B | $148.0M | ||
| Q3 25 | $1.3B | $1.6B | ||
| Q2 25 | $534.0M | $1.1B | ||
| Q1 25 | $725.0M | $1.1B | ||
| Q4 24 | $414.0M | $1.3B | ||
| Q3 24 | $2.5B | $1.8B | ||
| Q2 24 | $2.9B | $771.0M |
| Q1 26 | — | $816.0M | ||
| Q4 25 | $11.1B | $861.0M | ||
| Q3 25 | $11.1B | $858.0M | ||
| Q2 25 | $11.1B | $859.0M | ||
| Q1 25 | $10.5B | $853.0M | ||
| Q4 24 | $9.0B | $850.0M | ||
| Q3 24 | $9.2B | $849.0M | ||
| Q2 24 | $9.0B | $849.0M |
| Q1 26 | — | $15.7B | ||
| Q4 25 | $24.2B | $15.9B | ||
| Q3 25 | $23.4B | $15.4B | ||
| Q2 25 | $22.4B | $14.3B | ||
| Q1 25 | $22.2B | $13.7B | ||
| Q4 24 | $21.8B | $13.9B | ||
| Q3 24 | $20.7B | $13.8B | ||
| Q2 24 | $20.4B | $12.8B |
| Q1 26 | — | $41.2B | ||
| Q4 25 | $43.7B | $41.0B | ||
| Q3 25 | $42.7B | $40.6B | ||
| Q2 25 | $41.6B | $38.8B | ||
| Q1 25 | $40.1B | $37.3B | ||
| Q4 24 | $39.4B | $36.5B | ||
| Q3 24 | $38.1B | $37.0B | ||
| Q2 24 | $37.1B | $34.8B |
| Q1 26 | — | 0.05× | ||
| Q4 25 | 0.46× | 0.05× | ||
| Q3 25 | 0.48× | 0.06× | ||
| Q2 25 | 0.50× | 0.06× | ||
| Q1 25 | 0.47× | 0.06× | ||
| Q4 24 | 0.41× | 0.06× | ||
| Q3 24 | 0.45× | 0.06× | ||
| Q2 24 | 0.44× | 0.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
CINF
| Property casualty | $2.6B | 93% |
| Life | $105.0M | 4% |
| Other | $92.0M | 3% |
| Fee revenues | $1.0M | 0% |
